Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics grantee Bread of Life, Inc. hosted its third annual Community Baby Shower in Houston, supporting 100 expectant moms with essential baby items and health education. The event, part of the Quest for Health Equity (Q4HE) initiative, provided car seats, diaper bags, and other necessities to parents who may not have access to traditional baby showers.
Bread of Life Academy, which assists Houston's vulnerable population through education and workforce development, partnered with Community Health Choice to invite parents from their monthly distributions and outreach programs. The organization's community health workers addressed social determinants of health and provided connections to services.
This event is part of the ongoing collaboration between Bread of Life and the Quest Diagnostics Foundation, which began in 2022 with the launch of the Healthy Houston Collective program. The initiative aims to improve access to affordable healthcare and reduce health disparities in marginalized communities in Houston and surrounding areas.
Quest Diagnostics has completed its acquisition of LifeLabs from OMERS for approximately CAN $1.35 billion (USD $1 billion), including net debt. The transaction aims to enhance access to diagnostic innovation in North America. LifeLabs will continue to operate under its brand with the same management team and headquarters, while benefiting from Quest's expertise and resources.
The acquisition is expected to generate about CAN $970 million (USD $710 million) in annual revenues. It is anticipated to be slightly dilutive to GAAP EPS but $0.10-$0.15 accretive to adjusted EPS in the first 12 months after closing. Quest will provide updated financial guidance for 2024 in its Q3 earnings call in October.
Pat Beall shares her 32-year career journey at Quest Diagnostics, starting as a route service representative (RSR) and progressing to a supervisory role. She highlights the company's growth through acquisitions, emphasizing teamwork and client relationships in the Dallas-Fort Worth and northeastern Texas areas. Beall stresses the importance of patient service and personal initiative for career advancement at Quest. She values the opportunity to mentor new employees and encourages finding fulfillment in one's chosen career path. The story showcases Quest's employee development and long-term retention, reflecting positively on the company's work culture and growth opportunities.
Quest Diagnostics (NYSE: DGX) has announced a definitive agreement to acquire select assets of University Hospitals' outreach laboratory services business in Ohio. This strategic move aims to broaden access to Quest's innovative diagnostic services and extensive test menu across the state. The acquisition is expected to enhance operating efficiency and ensure continued access to affordable care.
Key points of the transaction include:
- Streamlined operations and quality maintenance
- Expanded patient access to Quest's convenient testing sites
- Broader health plan coverage
- Expected completion in Q4 2024, subject to regulatory approval
Financial terms were not disclosed, but the deal aligns with Quest's strategy to optimize laboratory services for quality, innovation, and affordability.
Quest Diagnostics' 2023 Corporate Responsibility Report, themed 'Care at Our Core', highlights the company's commitment to creating a healthier world. CEO Jim Davis emphasizes Quest's role in healthcare innovation and expansion of disease-state testing. Key achievements include:
- Acquisition of Haystack Oncology to improve cancer detection
- Expansion of Alzheimer's test portfolio
- Progress in Quest for Health Equity (Q4HE) initiative with 55 active programs
- Introduction of Quest Mobile™ phlebotomy service
- Relaunch of HealthyQuest employee health program
The report underscores Quest's focus on growth, efficiency, and new solutions to meet customer needs while expanding access to diagnostic services and reducing health disparities.
Quest Diagnostics (NYSE: DGX) has priced a public offering of $1.85 billion in senior notes, consisting of $400 million due 2027 at 4.600%, $600 million due 2029 at 4.625%, and $850 million due 2034 at 5.000%. The offering is expected to close on August 19, 2024. The proceeds will primarily fund the acquisition of LifeLabs, Inc. and for general corporate purposes, potentially including the redemption of $600 million in 3.50% senior notes due 2025. The 2027 and 2029 notes are subject to a special mandatory redemption at 101% of the principal amount if the LifeLabs acquisition is not completed. This offering provides Quest Diagnostics with significant financial flexibility for its strategic initiatives and debt management.
Quest Diagnostics (NYSE: DGX) has introduced 13 new blood tests on questhealth.com to identify micronutrient deficiencies. These tests are designed for individuals who may have insufficient nutrient intake due to dietary restrictions, prescription medications, or chronic health conditions. The panels, ranging from $65 to $299, cater to specific needs such as food allergies, medication regimens, and chronic diseases like Celiac disease and thyroid disorders.
The tests involve physician oversight and can be purchased directly on questhealth.com. After a physician review, individuals can schedule a blood draw at one of Quest's 2,000+ patient service centers. Results are provided in an easy-to-read report on a secure patient portal, with the option to discuss results with an independent physician at no extra cost.
Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.75 per share. The dividend will be payable on October 21, 2024 to shareholders of record as of October 4, 2024. This announcement demonstrates Quest Diagnostics' commitment to returning value to its shareholders and reflects the company's financial stability and confidence in its future prospects.
A Quest Diagnostics study published in the Journal of Lower Genital Tract Disease reveals significant gaps in STI testing for pregnant women. Analyzing over 4 million pregnancies, researchers found that 4% of women tested positive for chlamydia or gonorrhea in the first trimester. Alarmingly, 35% of these women didn't receive a follow-up negative test before delivery, suggesting potential untreated infections. The study highlights inconsistencies in guideline-based care, with 2% of initially negative patients later testing positive during pregnancy. Researchers recommend improving adherence to existing guidelines and updating recommendations for STI testing to enhance maternal and newborn health outcomes.
Quest Diagnostics celebrated National Logistics Day on June 28th, honoring their logistics professionals who ensure specimen delivery to labs nationwide. The PR highlights Jamie Croft's 13-year journey with Quest, from stat driver to Advanced RSR. Jamie's story showcases Quest's commitment to employee growth and development within the healthcare industry.
Initially aspiring to roles like dental hygienist or nurse, Jamie found her calling in Quest's logistics team. She progressed from weekend route driver to stat position, learning various aspects of logistics operations. Jamie's experience underscores Quest's role in providing career opportunities and fostering a supportive work environment in the medical field.